Get started
Author

María Dolores Martín-Salvago

Observed names: M. D. Martín-Salvago, M. Dolores Martín-Salvago, M. Martin-Salvago, M.D. Martín-Salvago, María D. Martín-Salvago
ORCID: 0000-0002-4366-2587
Observed ORCID: 0000-0002-4366-2587
OpenAlex ID: A5079282175
Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2018 · Adrián González-González, Esperanza Muñoz-Muela, et al. · Clinical Cancer Research · 67
PDF
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
2008 · Alfonso Sánchez-Muñoz, Ana María García-Tapiador, et al. · Clinical & Translational Oncology · 57
De novo lipogenesis protects dormant breast cancer cells from ferroptosis and promotes metastasis
2024 · Beatriz Puente-Cobacho, Cintia Esteo, et al. · Redox Biology · 41
Decreased Expression of Calcium Receptor in Parathyroid Tissue in Patients with Hyperparathyroidism Secondary to Chronic Renal Failure
2003 · María D. Martín-Salvago, José L. Villar-Rodríguez, et al. · Endocrine Pathology · 34
Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study
2021 · B. Vieites, M. Á. López-García, et al. · Clinical & Translational Oncology · 20
Redox status in the sentinel lymph node of women with breast cancer
2017 · María Jesús Ramírez-Expósito, Nieves Urbano-Polo, et al. · Upsala Journal of Medical Sciences · 15
Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination?
2010 · Alfonso Sánchez-Muñoz, R. Dueñas-García, et al. · American Journal of Clinical Oncology · 14
Liquen plano pigmentoso inverso: fácil de diagnosticar, difícil de tratar
2011 · Ricardo Ruiz-Villaverde, Manuel Galán-Gutierrez, et al. · Piel · 8
Value of total tumor load as a clinical and pathological factor in the prognosis of breast cancer patients receiving neoadjuvant treatment. Comparison of three populations with three different surgical approaches: NEOVATTL Pro 3 Study
2023 · María Dolores Martín-Salvago, Magdalena Sancho, et al. · Breast Cancer Research and Treatment · 5
PDF
Validation of prognostic and predictive value of total tumoral load after primary systemic therapy in breast cancer using OSNA assay
2023 · Laia Bernet-Vegué, Carolina Cantero-González, et al. · Clinical & Translational Oncology · 3
PDF
Metabolic Rewiring of Dormant Breast Cancer Cells: ACSL3-Mediated Monounsaturated Fatty Acids Incorporation Prevents Ferroptosis
2025 · Laura Vera Ramirez, Beatriz Puente-Cobacho, et al. · Free Radical Biology and Medicine · 1
PDF
Abstract PS3-10-03: Genomic Platform (GP) Testing and Adjuvant Chemotherapy (CT) Use in Early-Stage hormone receptor-positive (HR+) /HER2 negative (HER2-) Breast Cancer (BC): Real-World Insights and Prognostic Factors
2026 · R. Urbano, R. García, et al. · Clinical Cancer Research
Supplementary Information_clean version from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Supplementary Table S3 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Supplementary Figure S3 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Supplementary Figure S1 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Supplementary Figure S2 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Supplementary Table S1 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Supplementary Table S2 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Data from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
Data from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
2023 · Adrián González-González, Esperanza Muñoz-Muela, et al.
65P Patient follow-up of NEOVATTL study
2021 · B. Vieites, M.Á. López-García, et al. · Annals of Oncology
Works count: 22
Citation count: 265
H-index: 8
I10-index: 7
Year
Topic
Type